SB 222200 manufacturers
- SB-222200
-
- $33.00
-
2026-07-17
- CAS:174635-69-9
- Purity: 99.97%
- Supply Ability: 10g
|
| | SB 222200 Basic information |
| Product Name: | SB 222200 | | Synonyms: | 3-METHYL-2-PHENYL-N-[(1S)-1-PHENYLPROPYL]-4-QUINOLINECARBOXAMIDE;3-Methyl-2-phenyl-N-((1S)-1-phenylpropyl)quinoline-4-carboxamide;SB222200//3-Methyl-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxaMide;(S)-3-METHYL-2-PHENYL-N-(1-PHENYLPROPYL)-4-QUINOLINECARBOXAMIDE;SB 222200;SB-222200; SB222200;CS-1124;4-Quinolinecarboxamide, 3-methyl-2-phenyl-N-[(1S)-1-phenylpropyl]- | | CAS: | 174635-69-9 | | MF: | C26H24N2O | | MW: | 380.48 | | EINECS: | | | Product Categories: | | | Mol File: | 174635-69-9.mol |  |
| | SB 222200 Chemical Properties |
| Melting point | 154℃ | | Boiling point | 553.5±50.0 °C(Predicted) | | density | 1.142 | | storage temp. | Sealed in dry,2-8°C | | solubility | DMSO: ~28 mg/mL, soluble | | form | solid | | pka | 12.88±0.46(Predicted) | | color | light yellow | | InChI | 1S/C26H24N2O/c1-3-22(19-12-6-4-7-13-19)28-26(29)24-18(2)25(20-14-8-5-9-15-20)27-23-17-11-10-16-21(23)24/h4-17,22H,3H2,1-2H3,(H,28,29)/t22-/m0/s1 | | InChIKey | MQNYRKWJSMQECI-QFIPXVFZSA-N | | SMILES | CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c3ccccc3)c4ccccc4 |
| Safety Statements | 22-24/25 | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| | SB 222200 Usage And Synthesis |
| Uses | 3-Methyl-2-phenyl-N-[(1S)-1-phenylpropyl]-4-quinolinecarboxamide is a chemical agent used in the preparation of acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor as antipsychotics (1,2). | | Definition | ChEBI: 3-methyl-2-phenyl-N-[(1S)-1-phenylpropyl]-4-quinolinecarboxamide is a member of quinolines. | | Biological Activity | Potent and selective non-peptide NK 3 receptor antagonist. K i values are 4.4, >100,000 and 250 nM for human NK 3 , NK 1 and NK 2 receptors respectively. Brain penetrant and active in vivo . | | in vivo | SB-222200 (5 mg/kg; 30 min pretreatment) produces inhibition of behavioral responses induced by NK-3 receptor-selective agonist senktide (HY-P0187) in mice[1].
SB-2222006 exhibits moderate oral bioavailability (rat 46%) and Cmax (rat 427 ng/mL) following oral administration (rat 10 mg/kg)[1].
SB-2222006 exhibits terminal elimination half-life (rat 1.9 h) due to high plasma clearance (56 mL/min/kg) following intravenous administration (rat 2.5 mg/kg)[1].
| Animal Model: | Male BALB/c mice (19-21 g)[1] | | Dosage: | 5 mg/kg | | Administration: | Oral administration | | Result: | Produced 57% inhibition of senktide-induced behavioral responses in mice. |
| Animal Model: | Male Sprague-Dawley rats (300-400 g)[1] | | Dosage: | 2.5 mg/kg for i.v.; 10 mg/kg for p.o. (Pharmacokinetic Analysis) | | Administration: | Intravenous injection and oral gavage | | Result: | Oral bioavailability (46%), T1/2 (1.9 h), Cmax (427 ng/mL). |
| | IC 50 | NK3 | | storage | Store at RT |
| | SB 222200 Preparation Products And Raw materials |
|